HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G/Gillette earnings

This article was originally published in The Tan Sheet

Executive Summary

P&G expects the dilutive impact of its Gillette acquisition to reduce EPS by $.25 - $.35 in the first year after closing and $.05 -$.10 in the second year, with positive EPS growth of $.01 - $.05 in the third year, the firm says in a June 20 SEC filing. P&G's near-term strategy "must focus on the successful integration of the Gillette business and delivery of growth and cost synergies," the filing states; the firms are rumored to be mulling the divestment of certain brands to appease regulators, including products in the oral care division. P&G and Gillette recently postponed shareholder votes on the merger to July 12 and 13, respectively (1"The Tan Sheet" May 30, 2005, p. 7)...

You may also be interested in...



P&G/Gillette Integration On Track, But Shareholder Meetings Postponed

Preparations for Procter & Gamble's integration of Gillette are proceeding as scheduled, according to a May 24 filing with the SEC

Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva

Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.

Long-Term Data Confirm Durability Of Medtronic’s DTM Back Pain Therapy

A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel